Aim
We tested fluorophore-conjugated anti-CD45.2 monoclonal antibodies (mAb) to optimize dosing and two-photon imaging parameters for leukocyte labeling in healthy mice and a venous microstroke model. Approach: We retro-orbitally injected anti-CD45.2 mAb at 0.04, 0.4, and 2mg/kg2mg/kg<math><mrow><mn>2</mn> <mtext> </mtext> <mi>mg</mi> <mo>/</mo> <mi>kg</mi></mrow> </math> into BALB/c mice and used flow cytometry to analyze antibody saturation. Leukocyte labeling in the cortical microvasculature was examined by two-photon imaging. We also tested the application of CD45.2 mAb in a pathological leukocyte-endothelial adhesion model by photothrombotically occluding cortical penetrating venules.
Conclusion
We show that the anti-CD45.2 mAb is a robust reagent for acute labeling of leukocytes during in vivo two-photon microscopy of the cortical microvasculature.
Results
We found that 0.4mg/kg0.4mg/kg<math><mrow><mn>0.4</mn> <mtext> </mtext> <mi>mg</mi> <mo>/</mo> <mi>kg</mi></mrow> </math> of anti-CD45.2 antibody intravenously was sufficient to label 95% of circulating leukocytes. There was no depletion of circulating leukocytes after 24 h at the dosages tested. Labeled leukocytes could be observed as deep as 550μm550μm<math><mrow><mn>550</mn> <mtext> </mtext> <mi>μ</mi> <mi>m</mi></mrow> </math> from the cortical surface. The antibody reliably labeled rolling, crawling, and adherent leukocytes in venules around the stroke-affected tissues.
Significance
To study leukocyte-endothelial interactions in a living system, robust and specific leukocyte labeling techniques are needed for in vivo two-photon microscopy of the cerebral microvasculature. Aim: We tested fluorophore-conjugated anti-CD45.2 monoclonal antibodies (mAb) to optimize dosing and two-photon imaging parameters for leukocyte labeling in healthy mice and a venous microstroke model. Approach: We retro-orbitally injected anti-CD45.2 mAb at 0.04, 0.4, and 2mg/kg2mg/kg<math><mrow><mn>2</mn> <mtext> </mtext> <mi>mg</mi> <mo>/</mo> <mi>kg</mi></mrow> </math> into BALB/c mice and used flow cytometry to analyze antibody saturation. Leukocyte labeling in the cortical microvasculature was examined by two-photon imaging. We also tested the application of CD45.2 mAb in a pathological leukocyte-endothelial adhesion model by photothrombotically occluding cortical penetrating venules. Results: We found that 0.4mg/kg0.4mg/kg<math><mrow><mn>0.4</mn> <mtext> </mtext> <mi>mg</mi> <mo>/</mo> <mi>kg</mi></mrow> </math> of anti-CD45.2 antibody intravenously was sufficient to label 95% of circulating leukocytes. There was no depletion of circulating leukocytes after 24 h at the dosages tested. Labeled leukocytes could be observed as deep as 550μm550μm<math><mrow><mn>550</mn> <mtext> </mtext> <mi>μ</mi> <mi>m</mi></mrow> </math> from the cortical surface. The antibody reliably labeled rolling, crawling, and adherent leukocytes in venules around the stroke-affected tissues. Conclusion: We show that the anti-CD45.2 mAb is a robust reagent for acute labeling of leukocytes during in vivo two-photon microscopy of the cortical microvasculature.